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SUMMARY
The aim was to evaluate the role of klotho in the pathogenesis of systemic sclerosis (SSc), through the measure-
ment of its serum concentration in SSc patients compared to healthy controls, and to assess the association with 
cutaneous and visceral involvement. 
Blood samples obtained from both SSc patients and healthy controls were analysed by an ELISA assay for 
the detection of human klotho. SSc patients were globally evaluated for disease activity and assessed through 
the modified Rodnan’s Skin Score, Medsger’s scale, pulmonary function tests, 2D-echocardiography, nailfold 
capillaroscopy and laboratory tests. 
Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 
(IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, 
19 (27.5%) suffered from a diffuse form of SSc. All patients were receiving IV prostanoids, and some of 
them were concomitantly treated with immunosuppressive drugs (prednisone, hydroxychloroquine, mofetil 
mycophenolate, methotrexate, cyclosporin A and azathioprine). The median serum concentration of klotho was 
significantly lower in patients compared to controls (0.23 ng/mL vs 0.60 ng/mL; p<0.001). However, Spear-
man’s test showed no significant association between klotho serum levels and disease activity, concerning either 
clinical, laboratory or instrumental findings. 
Our data show a significant deficit of klotho in SSc patients although any significant association was detected 
between klotho serum concentration and the clinical, laboratory or instrumental features of the disease. How-
ever, due to the limits of the study, further investigations are required. 
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n	 INTRODUCTION
Systemic sclerosis (SSc) is a connec-tive tissue disease characterized by a 
microvessel dysfunction, the aberrant acti-
vation of the immune system, and the de-
position of extracellular matrix in skin and 
viscera. Endothelial cells and contractile 
myofibroblasts, involved in microvessel 
dysfunction, contribute to the first step in 
the pathogenesis of the disease, whereas 
the immune system may play a second-
ary role. Klotho is a trans-membrane, 
soluble and secreted protein that displays 
enzymatic and co-receptor functions, be-
ing involved in the prevention of aging, in 
the calcium-phosphate balance and in the 
reparative and fibrotic processes (1, 2). 
Transgenic klotho-/- mice develop a phe-
notype characterized by accelerated aging, 
atherosclerosis, hyper-phosphatemia, os-
teoporosis, cutaneous atrophy and emphy-
sema and have a lower likelihood in cuta-
neous wound healing (3). As klotho seems 
to play an essential role in the maintenance 
of vessel tone control, in tissue regenera-
tion and reparation and in the electrolytic 
balance, a deficit in the concentration of 
this molecule could explain some pheno-
typic aspects of SSc, like microvessel dys-
function, calcinosis and fibrosis.
The primary objective of this study was to 
evaluate klotho as a biomarker of SSc, to 
measure its concentration as a soluble mol-
ecule in the peripheral blood of SSc pa-
tients and to compare it with healthy con-
trols. The secondary objective was to find 
any significant association with clinical, 
laboratory and instrumental manifestations 
of the disease. 
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n	 MATERIALS AND METHODS
Sixty-nine consecutive SSc patients, ac-
cording to the 2013 EULAR/ACR criteria 
(4), and 77 healthy controls were enrolled 
in our study. After signing an informed 
consent, venous blood samples obtained 
from both patients and controls were col-
lected and centrifuged. Sera were analysed 
through an ELISA assay, aiming to detect 
the human soluble klotho by means of a 
monoclonal anti-KL antibody and a KL-
HRP conjugate (My Biosource, CA, USA), 
with a sensitivity of 0.1 ng/mL.
SSc patients were assessed for the most 
specific clinical manifestations (including 
Raynaud’s phenomenon, digital ulcers, cal-
cinosis), through the Medsger’s scale score 
(5) for the severity of global visceral in-
volvement and through the modified Rod-
nan’s Skin Score (mRSS) for cutaneous 
involvement. Moreover, the demographic 
and clinical data concerning pulmonary 
function tests (forced vital capacity or 
FVC; diffusing capacity/transfer factor 
of the lung for carbon monoxide per unit 
alveolar volume or DLCO/AV; chest high 
resolution computer tomography or HRCT 
scan), cardiac indexes (2D echocardiogra-
phy or 2D-ECHO) as indirect estimator of 
the risk of pulmonary artery hypertension 
(PAH), nailfold capillaroscopic pattern and 
laboratory tests (serum creatinine level; 
erythrocyte sedimentation rate or ESR; 
C-reactive protein or CRP; autoantibod-
ies), as well as concomitant pharmacologic 
treatments were also recorded for every 
single patient.
Since klotho may be involved in the pre-
vention of diabetes, renal failure and bron-
chial obstructive disease, these disorders 
were considered as exclusion criteria. 
Statistical analysis
Parametric and non-parametric statistical 
tests according to data distribution have 
been used. When data were parametri-
cally distributed, results were reported as 
mean±standard deviation (SD); when data 
were not parametrically distributed, we re-
ported the results as median, interquartile 
interval (IQ) and range. A two-tailed Mann 
Whitney U test for unpaired samples was 
used to compare the serum concentration 
of klotho between patients and controls. In 
the group of SSc patients, Spearman’s test 
was used to correlate the level of klotho 
with clinical, laboratory and instrumental 
findings. Statistical analysis was carried 
out using a SPSS calculator, version 23, 
setting the P-value at <0.05.
n	 RESULTS
Sixty-nine consecutive SSc patients (61 
females, mean age±SD 64.5±12.5 years, 
median (IQ) disease duration 9.0 (8) years) 
and 77 healthy controls (28 females, mean 
age±SD 49.7±10.2 years) were enrolled 
in the study. In the group of SSc patients, 
19 (27.5%) suffered from a diffuse form 
of disease. Antinuclear antibodies (ANA) 
were detected in 64 (92.7%) patients, anti-
centromere (anti-CENB) autoantibodies in 
34 (49.2%) patients and anti-Scl70 auto-
antibodies in 17 (24.6%) patients. In order 
to counteract Raynaud’s phenomenon and 
prevent digital ulcers, all patients were re-
ceiving intravenous (IV) prostanoids, and 
21 patients were concomitantly treated 
with calcium channel blockers (CCBs). 
Seven patients were taking bosentan for 
the treatment of PAH and the prevention 
of digital ulcers. None of the patients were 
treated with phosphodiesterase-5 inhibi-
tors. In addition, several patients were also 
treated with immunosuppressive drugs 
(prednisone 2.5-5 mg/day in 5 cases, hy-
droxychloroquine 200-400 mg/day in 14 
cases, mofetil mycophenolate 1-2 g/day 
in 3 cases, methotrexate 7.5-15 mg/week 
in 6 cases, cyclosporin A 100 mg/day in 1 
case and azathioprine 100-150 mg/day in 
5 cases). The median (IQ) ESR and CRP 
values were respectively 13.0 (25) mm 1st 
h and 2.2 (3.7) mg/L and overall median 
creatinine levels were within the normal 
range (0.78 mg/dL; IQ 0.33). The median 
mRSS score was 5 (IQ 9) with a range 
between 1 and 30, and values higher than 
20 were reported only in 5 cases. Digital 
ulcers were actively present in 16 (23.1%) 
patients and were managed with IV pros-
tanoids and topical medications; calcinosis 
in 11 (15.9%) patients; 11 (15.9%) patients 
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were at risk of PAH, detected by means of 
2D-ECHO and 30 (43.4%) patients had 
lung fibrosis, detected by means of chest 
HRTC. Pulmonary function was globally 
preserved [median (IQ) DLCO/VA 86% 
(20); median (IQ) VC 98% (20)]. DLCO 
was below 80% in 25 patients, but in the 
majority of the cases fibrosis affected less 
than 20% of lung parenchyma and DLCO 
reduction was in general due to the con-
comitant PAH. No significant association 
between lower DLCO values and lung 
pulmonary fibrosis or PAH has been found 
(p>0.05). On the contrary, VC was below 
70% only in 2 cases and significantly lower 
in SSc patients with lung fibrosis (p=0.001, 
95%CI 5.15-19.17). 
Additionally, we obtained the nailfold cap-
illaroscopic images at the time of recruit-
ment from 42 patients, which were scored 
according to Cutolo et al. (6). Eight of 
them (19%) had a normal pattern, 7 (16%) 
an early SSc pattern, 16 (38%) an active 
SSc pattern and 11 (26%) a late SSc pat-
tern. Being a qualitative assessment, the 
capillary pattern was considered as a dico-
thomous variable (normal versus patholog-
ical). Finally, 23 (33.3%) patients suffered 
from osteoporosis and 20 of them were 
taking calcium supplements and cholecal-
ciferol.
The demographic and clinical character-
istics of the SSc cohort are reported in 
Table I.
In the group of SSc patients, the median 
concentration of serum klotho was 0.23 ng/
mL (IQ 0.61, range 0.04-1.85) with a non-
Gaussian distribution, while in the control 
group, mean serum klotho concentration 
was 0.59±0.39 ng/mL, with a normal dis-
tribution. When descriptive statistical tests 
were performed on the global cohort, a 
non-Gaussian distribution of overall klotho 
values was obtained, after which we chose 
non parametric tests for the following anal-
yses. Using a two-tailed Mann Whitney 
Table I - Demographic and clinic characteristics of the cohort of scleroderma patients. 
SSc patients, n. 69
Age (years), mean±SD 64.5±12.5
Gender (F/M), n. (%) 61/8 (88.4%/11.5%)
Disease duration (years), median, IQ; range 9, 8; 1-57
Clinical form (limited/diffuse), n.(%) 50/19 (72.4%/27.5%)
ANA+, n. (%) 64 (92.7%)
Anti-CENB+, n. (%) 34 (49.2%)
Anti-SCL70+, n. (%) 17 (24.6%)
ESR (1 h mm), median, IQ; range 13, 25; 2-84
CRP (mg/L), median, IQ; range 2.2, 3.7; 0-24
Serum creatinine (mg/dL), median, IQ; range 0.78, 0.33; 0.49-2.22
Digital ulcers, n. (%) 16 (23.1%)
Calcinosis, n. (%) 11 (15.9%)
PAH, n. (%) 11 (15.9%)
Lung fibrosis, n. (%) 30 (43.4%)
DLCO/AV (%), median, IQ; range 86, 20; 49-118
FVC (%), median, IQ; range 98, 20; 58-138
Medsger’s Scale Score, median, IQ; range 4, 2.5; 0-12
mRSS, median, IQ; range 5, 9; 1-30
Osteoporosis, n. (%) 23 (33.3%)
SSc, systemic sclerosis; SD, standard deviation; IQ, interquartile interval; F/M, female/male; ANA, anti-
nuclear antibodies; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PAH, pulmonary artery 
hypertension; DLCO/AV, diffusing capacity/transfer factor of the lung for carbon monoxide per unit alveo-
lar volume; FVC, forced vital capacity; mRSS, modified Rodnan’s skin score.
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U test for unpaired samples, a significant 
reduction in serum klotho concentration in 
patients compared to controls was detected 
(p<0.001), Figure 1.
However, the cohorts of patients and con-
trols significantly differed for gender 
(p<0.001) and age (p<0.001). Global me-
dian concentration of serum klotho was 
0.27 ng/mL (IQ 0.61; range 0.00-1.85) in 
females and 0.63 ng/mL (IQ 0.68, range 
0.00-1.70) in males, with a significant 
difference between males and females 
(p<0.001). Among controls, median serum 
klotho concentrations were lower in fe-
males (median values 0.45 ng/mL; IQ 0.46, 
range 0.00-1.10) than males (median val-
ues 0.71 ng/mL, IQ 0.51, range 0.00-1.70), 
although this difference was not statistical-
ly significant (2-tailed T-test for unpaired 
samples; p=0.27); on the contrary, in the 
patients’ group median klotho serum con-
centrations were higher in females (median 
values 0.24 ng/mL; IQ 0.66, range 0.04-
1.85) than males (median values 0.19 ng/
mL, IQ 0.15, range 0.13-0.37) and this dif-
ference was statistically significant (two-
tailed Mann Whitney U test for unpaired 
samples; p=0.02). Age minimally affected 
the concentration of klotho in the overall 
population (p=0.05; F 3.89; p=0.26), al-
though not reaching significance when 
the group of SSc patients and controls 
were analysed separately (p=0.47; F 0.52; 
p=0.008 for SSc patients and p=0.48; 
F 0.49; p=0.007 for controls). 
In the group of SSc patients, Spearman cor-
relation showed no significant association 
between klotho serum levels and disease 
activity, concerning either clinical, labora-
tory and instrumental findings.
n	 DISCUSSION
Klotho is a 130 kDa protein synthetized 
in many tissues as a soluble, secreted or 
single-pass trans-membrane form, initially 
considered as an anti-aging factor. Three 
genes are responsible for the codification of 
the a, b and g isoforms of klotho. a-klotho 
is mainly produced in the arterial tree, skin, 
kidney and gut epithelia, neuronal cells and 
endocrine tissues (7). b-klotho, sharing a 
41% amino acid homology with a-klotho, 
is expressed in adipose tissue, liver and 
pancreas (8). The entire molecule of klotho 
contains a single-pass trans-membrane 
domain and two extracellular domains, 
known as KL1 and KL2 domains and, fol-
lowing a mechanism of alternative splic-
ing, a secreted isoform of klotho, contain-
ing only the KL1 domain, may be gener-
ated and released in the extracellular envi-
ronment. Furthermore, once expressed on 
the cellular surface, the extracellular KL1 
and KL2 domains may be cleaved by secre-
tases and released as soluble klotho (9). 
Trans-membrane klotho may interact with 
receptors on neighbouring cells, acting in 
a paracrine axis, whereas soluble klotho 
may circulate in the bloodstream and ex-
ert its effects on distant organs as an en-
docrine factor. The KL1 and KL2 domains 
of both transmembrane and soluble klotho 
display b-glucuronidase and sialidase ac-
tivity by removing glucidic residuals from 
transient receptor potential vanilloid recep-
tor-related (TRPV5) and TRP canonical-1 
(TRPC-1), thus regulating calcium (Ca)2+ 
ions influx into epithelial and endothelial 
Figure 1 - Median serum concentration of klotho in systemic scle-
rosis patients and healthy controls. 2-tailed Mann Whitney U test for 
unpaired sample. SSc pt, systemic sclerosis patients; HC, healthy 
controls. 
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cells (10). A deficiency in klotho may re-
duce the internalization into vascular cells 
of the complex TRPC-1/vascular endothe-
lium growth factor receptor (VEGFR) that 
usually follows stimulation with VEGF, 
with a subsequent increase in the amount 
of intracellular Ca2+ finally responsible for 
the Ca2+-dependent activation of calpain 
and caspase-3, which promote endothe-
lial permeability and cell disruption (10). 
Similarly, klotho may regulate the influx of 
sodium and potassium in cardiac, renal and 
nervous cells. 
Soluble and trans-membrane klotho may 
also act as coreceptor, recognizing and 
strengthening the interaction between fi-
broblast growth factor (FGF) members 
and their receptors. a-klotho may com-
plex with FGF23 and FGFR1c in the prox-
imal tubules of the kidney and suppress 
the 1a-hydroxylation of 25(OH)2 vitamin 
D, thus reducing Ca2+ and phosphate re-
sorption. The excessive concentration of 
phosphate favours the constriction of ves-
sels and the generation of reactive oxygen 
species (ROS). A group of researchers 
demonstrated that the addition in vitro of 
soluble klotho to human smooth vascular 
cells or human umbilical vein endothelial 
cells contrasts phosphate- and FGF23-
mediated vasoconstriction, by increasing 
the production of nitric oxide (NO) (11). 
Furthermore, the authors demonstrated in 
the same experiment that the addition of 
soluble klotho without FGF23 to mouse 
aorta rings induced vasoconstriction and 
the production of ROS. The increase in 
endothelial NO following soluble klotho 
administration could explain the antago-
nistic effects of klotho to monocrotaline-
induced experimental PAH in murine 
models (12). However, the evaluation of 
soluble a-klotho in the peripheral blood 
from 64 precapillary PAH patients did not 
find a significant association with haemo-
dynamic findings (13). It suggests that 
soluble klotho exerts its hormonal effects 
modulating the vessel tone according to the 
presence or not of FGF23 and that a- and 
b-klotho may have different roles in con-
trolling myo-contractile cells and in pre-
serving endothelial integrity. Moreover, it 
has been demonstrated that b-klotho, but 
not a-klotho, complexes with FGF19 and 
FGFR4 expressed in the biliary tract, con-
trolling bile acid synthesis (14). b-klotho 
may account for the glucidic and lipidic 
balance, reducing insulin resistance and 
visceral adiposity, and contributing there-
fore to minimize vascular damage through 
different biologic mechanisms. A deficit 
of klotho has been associated with oxi-
dative stress and mitochondrial damage, 
which represent specific hallmarks of the 
endothelial dysfunction in SSc, and to the 
modulation in the expression of p53 and 
p21 that accelerates the cell-cycle arrest 
in G1 phase and cell senescence, gener-
ating oxidative stress and autophagy (9). 
Moreover, soluble klotho binds to several 
Wnt proteins inhibiting their biological 
activity, including keratinocyte ageing 
and connective tissue fibrosis. Klotho-/- 
mice have a short lifespan and an elderly 
phenotype characterized by a deficit in 
osteoclasts and osteoblasts, diffuse bone 
demineralization and vascular tree calcifi-
cations. It has been reported that a deficit 
in human klotho may account for severe 
tumoral calcinosis (15). Subcutaneous 
calcinosis is a common finding in SSc 
and a deficit in serum klotho concentra-
tion could be responsible for Ca2+ lumps. 
Moreover, a deficit in klotho could induce 
a delay in cutaneous ulcer healing related 
to a reduced apposition of collagen 1 and 
3 in wound tissue (3). However, although 
SSc patients often suffer from prolonged 
cutaneous ulcer healing times, the reduced 
production of collagen observed in klotho-
deficient mice contrasts with the aberrant 
deposition of extracellular matrix in SSc. 
A recent experiment on human primary 
dermal microvascular endothelial cells 
and dermal fibroblasts showed that klotho 
may control the expression of genes in-
volved in tissue repair and angiogenesis, 
counteracting the aberrant production of 
extracellular matrix and favouring neo-
vessel sprouting (16). The possible path-
way presided by a- and b-klotho is illus-
trated in Figure 2.
Our data demonstrate that the median 
serum concentration of klotho was sig-
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nificantly lower in SSc patients than in 
healthy controls. These results are in ac-
cordance with the hypothesis that a deficit 
of klotho may account for many manifes-
tations of the disease, including ulcer heal-
ing delay, lung fibrosis, calcinosis, renal 
crisis. Although a standardised range for 
serum klotho is unavailable, our results 
are in line with serum klotho levels shown 
in previous studies on human healthy sub-
jects (17, 18). However, due the consecu-
tive enrolment and the design of the study, 
the cohort of patients significantly differed 
from controls with respect to gender and 
age. Klotho concentrations were lower 
in patients than in controls both in males 
and females, with the lower concentra-
tions in male patients. Gender may have 
represented a bias for our analysis; never-
theless, SSc may play an additional role in 
influencing klotho serum levels, altering 
the male/female ratio in the group of pa-
tients. However, two previous studies mea-
suring serum klotho concentration through 
an ELISA kit in healthy subjects did not 
suggest a significant influence of gender 
on klotho serum concentration (17, 19). 
Furthermore, other studies on non-sclero-
derma-patient populations reported higher 
serum klotho concentrations in female 
than in male patients (20, 21). These data 
are in line with our results, and may sug-
gest that chronic diseases, including SSc, 
induce an imbalance of the serum klotho 
concentration with a more pronounced ef-
fect on male patients. 
On the contrary, age did not affect the over-
all concentration of serum klotho in both 
cohorts. 
Unfortunately, to our knowledge, no evalu-
ation of soluble klotho in the sera of pa-
tients affected by connective tissue diseas-
es has been reported until today. A reduced 
concentration of a-klotho in the cerebro-
spinal fluid has been associated to neuro-
psychiatric systemic lupus erythematosus 
(NSLE) in a multivariate analysis on 84 
neuropsychiatric patients (22). Similarly, 
an impairment in genetic expression and a 
deficient b-glucuronidase activity of klotho 
has been demonstrated in CD4+ T lym-
phocytes from rheumatoid arthritis (RA) 
patients, and associated with premature 
senescence of this pool of cells (23). In a 
murine model of autoimmune colitis, it has 
been demonstrated that cytokines tumour 
necrosis factor (TNF) and interferon-g re-
duced the transcription of the klotho gene 
in renal epithelial cells (24).
SSc seems to display many phenotypic as-
pects compatible with a deficit of klotho. 
However, we did not find any significant as-
sociation between the serum concentration 
of klotho and the likelihood of undergoing 
a specific manifestation of the disease. The 
most important limits of this study consist 
in the number of subjects involved, in the 
enrolment of patients coming from mis-
matched cohorts for gender and age, in 
the measurement of whole soluble klotho 
(without any distinction between a-klotho 
and b-klotho), in the lack of evaluation 
of secreted, soluble and trans-membrane 
isoforms, and perhaps in the low sensitiv-
Figure 2 - Biologic pathways presided by a and b-klotho. Klotho is 
mainly synthetized in renal distal convolute tubules, cerebral choroid 
plexus, epithelial cells and vascular tree, as a 130kD peptide con-
taining a transmembrane domain and two extracellular domains. Fol-
lowing a mechanism of alternative splicing, a short form of secreted 
klotho, having only the KL1 extracellular domain may be produced. 
Once expressed on the plasma membrane, transmembrane klotho 
may be cleaved by extracellular secretases in a soluble form (a- and 
b-klotho) that may act as b-glucuronidase or coreceptor, complex-
ing with FGF and FGFR. b-klotho is prevalently involved in electro-
lytic balance, endothelium integrity, vessel tone control and fibrosis 
prevention. b-klotho seems to preside to the control of biliar salt se-
cretion and insulin sensitivity. TM, transmembrane; FGF, fibroblast 
growth factor; FGFR, fibroblast growth factor receptor.
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ity of the ELISA test. Polymorphic vari-
ants of the klotho gene were not assessed, 
since they could explain a quantitative or a 
qualitative deficit of the molecule. Finally, 
given the central role of klotho in calcium/
phosphate balance and in bone remodel-
ling, the regular intake of calcium and 
cholecalciferol in 20 osteoporotic patients 
and the lack of a control group could have 
added further bias to our analysis, although 
no significant association was recorded be-
tween serum klotho concentration and the 
odds of having osteoporosis in the SSc co-
hort. Moreover, a recent work by Chalhoub 
et al. failed to assign sufficient relevance to 
soluble klotho as a biomarker of bone re-
sorption and fracture risk (25).
n	 CONCLUSIONS
Our data show a reduced concentration of 
serum klotho in patients affected by SSc 
compared to healthy controls with no sig-
nificant correlation with clinical, laborato-
ry or instrumental features of the disease. 
Many experiments in vitro and in vivo 
have demonstrated an important role of 
klotho in the control of vessel tone, tissue 
reparation, ectopic calcifications, elec-
trolytic balance and wound healing, and 
some of these aspects are shared by SSc. 
Due to the limits of our study, the results 
obtained failed to show any significant as-
sociation with the phenotypic characteris-
tics of the disease and further investiga-
tions are indeed needed in order to better 
understand the real involvement of klotho 
on the pathogenesis of SSc.
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